Sheba Hospital last month began giving fourth vaccine For more than 270 medical workers – 154 who received the Pfizer-Biontech vaccine and another 120 who received the Moderna vaccine. They were all previously vaccinated three times with the Pfizer-Biontech vaccine.
The clinical trial found that both groups showed an increase in antibodies “slightly higher” than following the third dose of the vaccine last year. But, she said, the increased antibody did not prevent the spread of the omicron.
“Despite an increase in Antibody levelsHowever, the fourth vaccine offers only partial defense against the virus… Vaccines, which were more effective against previous variants, provide less protection compared to Omicron.”
The initial findings raised questions about Israel’s decision to provide a second booster dose – and a fourth overall – to its population over the age of 60. The government says more than 500,000 people have received the second dose in recent weeks.
Dr. Nahman Asch, director of the Israeli Ministry of Health, said the research does not mean that the fourth vaccine effort was wrong. “It brings back the standard Antibodies to what it was at the beginning of the third reinforcer. “This is of great importance, especially among the older population,” he told Channel 13 TV.
But he said the research will be taken into account while authorities debate whether to expand a campaign booster dose additional to include all residents.